# Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product

Source: https://onco.cc/ideas/idea-reg-vein-to-vein-public-benchmark/  
OnCo record `idea-reg-vein-to-vein-public-benchmark` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Patients and doctors cannot see how long each CAR-T maker takes or how often manufacturing fails. Publishing this would create pressure to get faster and more reliable.

## Summary

Vein-to-vein times for commercial CAR-T range from roughly three to eight weeks and out-of-specification rates from a few percent to over ten, but these figures appear only in trial publications and investor slides. The proposal is a regulatory condition that each approved cell therapy reports, quarterly and publicly, median and 90th percentile apheresis-to-infusion time, out-of-specification and manufacturing failure rates, and the proportion of enrolled patients never infused, stratified by country.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Public benchmarking is followed by a fall in median vein-to-vein time of at least a week across the market within two years and convergence of failure rates towards the best performer.
- Rationale: Public reporting of hospital outcomes and airline punctuality changed behaviour where private reporting did not. Manufacturers already collect these data for their own control; publication is cheap.
- Proposed test: Begin with voluntary reporting through a registry such as CIBMTR or EBMT, publish two years of data, and evaluate whether times and failure rates changed relative to the prior period.
- Maturity: speculative
- Actor: regulator

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- drugs: [Axicabtagene ciloleucel](https://onco.cc/drugs/axicabtagene-ciloleucel/), [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-vein-to-vein-public-benchmark.json